
    
      Two vaccines will be administered: V934-electroporation (EP) either low dose (LD) or high
      dose (HD), and V935 either LD or HD. In Part A, participants will be assigned to V935 vaccine
      alone or in combination with V934-EP. Part B will be an optional part of the study, offering
      V934-EP vaccine booster to participants who were enrolled in Part A.
    
  